Therefore, the broad spectrum of cancer phenotypes potentially accompanying the germline alterations in CDKN2A suggests that it could be regarded as a candidate for tumor predisposition beyond melanoma and pancreatic cancer in clinical practice30,39. This evidence concerns the gene CDKN2A and neoplasm.